Metastatic Renal Cell Carcinoma: The Importance of Immunohistochemistry in Differential Diagnosis

Introduction: Clear cell carcinoma accounts for 75% of all types of renal neoplasms. Approximately one third presents with metastatic disease at diagnosis. Immunohistochemical studies play a significant diagnostic role. Case Report: We report the case of a 48-year-old heavy smoker who presented with productive cough and progressive dyspnea. The study revealed a renal mass and lung alterations compatible with primary tumor of the lung. The patient underwent a right complete nephrectomy. The anatomopathological exam showed clear cell renal carcinoma (pT1bN0Mx). After transthoracic needle aspiration biopsy, the clinical diagnosis was stage IV adenocarcinoma of the lung. Initially, the patient received one cycle of chemotherapy (cisplatin/pemetrexed). Two weeks later, the immunohistochemistry tests revealed a secondary lesion with probable renal origin. Chemotherapy was stopped and the patient was started on sunitinib treatment. After two cycles the disease progressed. A second-line treatment with everolimus was proposed; however, the patient died 2 weeks later due to terminal respiratory insufficiency. Discussion: Clear cell renal cell carcinoma remains one of the great mimickers in pathology. Immunohistochemistry is a valuable tool in the differential diagnosis of lung carcinomas. With the help of thyroid transcription factor 1, it is possible to distinguish a primary lung tumor from a metastasis with a reasonable degree of certainty. The present case report illustrates the challenge of making a definitive and adequate diagnosis. The immunohistochemistry added information that changed the whole treatment strategy. For the best treatment approach, it is fundamental that clinicians await all possible test results, before establishing a treatment plan

Procedimiento para producir plaquetas humanas a partir de células en cultivo.

Se describe un procedimiento para obtener cantidades ilimitadas de plaquetas humanas a partir de las líneas celulares K562 y KU812, derivadas de leucemias mieloides. El procedimiento se basa en el tratamiento con estaurosporina a concentraciones 50 a 100 nM durante 3 a 6 días. Las células pueden crecerse en suspensión y las plaquetas pueden ser separadas de las células por métodos estándar. Las plaquetas son reconocibles morfológicamente y comparten características bioquímicas y ultraestructurales con las plaquetas aisladas de sangre. Se puede obtener así una preparación de plaquetas humanas a partir de precursores celulares genéticamente idénticos y libre de otros productos biológicos de origen humano. Pueden ser usadas para fines analíticos como servir de estándar en ensayos plaquetarios biológicos o bioquímicos.Solicitud: 009900666 (05.04.1999)Nº Pub. de Solicitud: ES2155379A1 (01.05.2001)Nº de Patente: ES2155379B1 (01.12.2001

Development of a new chitosan hydrogel for wound dressing

Wound healing is a complex process involving an integrated response by many different cell types and growth factors in order to achieve rapid restoration of skin architecture and function. The present study evaluated the applicability of a chitosan hydrogel (CH) as a wound dressing. Scanning electron microscopy analysis was used to characterize CH morphology. Fibroblast cells isolated from rat skin were used to assess the cytotoxicity of the hydrogel. CH was able to promote cell adhesion and proliferation. Cell viability studies showed that the hydrogel and its degradation by-products are noncytotoxic. The evaluation of the applicability of CH in the treatment of dermal burns in Wistar rats was performed by induction of full-thickness transcutaneous dermal wounds. Wound healing was monitored through macroscopic and histological analysis. From macroscopic analysis, the wound beds of the animals treated with CH were considerably smaller than those of the controls. Histological analysis revealed lack of a reactive or a granulomatous inflammatory reaction in skin lesions with CH and the absence of pathological abnormalities in the organs obtained by necropsy, which supported the local and systemic histocompatibility of the biomaterial. The present results suggest that this biomaterial may aid the re-establishment of skin architecture

Bacillary Prostatitis after Intravesical Immunotherapy: A Rare Adverse Effect

Nowadays, the most efficient form of intravesical immunotherapy for superficial transitional cell carcinoma of the urinary bladder is the instillation of bacillus Calmette-Guérin (BCG), proceeding from an attenuated strain of Mycobacterium bovis. In up to 40% of cases, its instillation is associated with significantly elevated prostate-specific antigen (PSA) levels. In these cases, prostate biopsy should be withheld for 3 months and PSA should be monitored. Bacillary prostatitis is a rare occurrence in patients treated with intravesical BCG immunotherapy. Although symptomatic bacillary prostatitis is even rarer, it is the worst type of this condition. The aims of this study are to report a case of bacillary prostatitis as a rare adverse effect of intravesical BCG immunotherapy and to make a theoretical review about how to manage this complication. A 58-year-old man, former smoker, underwent a transurethral resection of the bladder in February 2004 because of a papillary transitional cell carcinoma of the bladder (pT1G2N0M0). After surgery, BCG instillation therapy was given in a total of 15 instillations, the last one in March 2007. In the last 3 months of therapy, until May 2007, a progressive increase in his PSA level was registered, and he underwent a prostate biopsy revealing granulomatous prostatitis of bacillary etiology. The semen culture was positive for M. bovis. After 3 months of a two-drug (isoniazid and rifampin) antituberculous regimen, the semen culture became negative and the PSA level decreased. The early identification of intravesical BCG immunotherapy complications allows their effective treatment. However, when a histological diagnosis of asymptomatic granulomatous prostatitis is made, the execution and type of treatment are controversial

INNOVASONORA: gestión de archivos sonoros, sonido inmersivo y realidad virtual en plataformas LMS

Memoria del proyecto de innovación docente "Innovasonora" (Curso 2021-2022

INNOVASONORA: desarrollo de recursos para la transmisión digital de los archivos sonoros y la aplicación de la realidad virtual como complemento de la enseñanza presencial

Memoria del proyecto de innovación docente nº 208 (curso 2020-2021

La influencia de la tecnología en los procesos de producción musical: análisis de la grabación sonora y sus aplicaciones en el ámbito docente

Memoria de las actividades del proyecto de Innova-Docencia nº256, coordinado por el Dr. Marco Antonio Juan de Dios Cuartas, profesor del Departamento de Musicología de la Universidad Complutense de Madrid

El laboratorio sonoro como herramienta docente para el análisis de la creación e interpretación musical a través de las grabaciones

Depto. de MusicologíaFac. de Geografía e HistoriaFALSEsubmitte

Produção de matrizes à base de quitosano para o tratamento de feridas

A pele é o maior órgão do corpo humano cuja função é comprometida pela ocorrência de feridas. O tratamento de feridas representa uma fracção considerável dos gastos em saúde, sendo o desenvolvimento de novos métodos de tratamento alvo de grande interesse. Uma das vertentes desta investigação é a utilização de novas matérias-primas na produção de dispositivos médicos(DM) para o tratamento de feridas. O quitosano é um derivado da quitina, o segundo biopolímero mais abundante. As propriedades biológicas do quitosano tornam-no um bom candidato à produção de dispositivos médicos. Este trabalho teve como objectivo o desenvolvimento de DM para o tratamento de feridas à base de quitosano. Foram desenvolvidos três dispositivos: um hidrogel obtido a partir da coagulação de uma solução de quitosano, uma matriz porosa por liofilização, e uma matriz combinada de microfibras e nanofibras por fiação húmida e electrofiação, respectivamente. Verificou-se que o quitosano acelera o processo de cicatrização de feridas, levando a uma diminuição mais rápida do seu tamanho quando comparado com o tratamento tradicional e uma reepitelização compatível com um processo de regeneração adequado. O melhor desempenho no tratamento de feridas foi obtido com a utilização da matriz combinada pela conjugação das propriedades biológicas do quitosano com a elevada área superficial das nanofibras. Neste trabalho foram comparados pela primeira vez em paralelo três produtos à base de quitosano com características distintas como DM para o tratamento de feridas. O sucesso da concepção e desenvolvimento do hidrogel e da matriz porosa de quitosano permitiu a sua certificação e industrialização com os nomes comerciais HidroKi® e AbsorKi®, respectivamente. Concluiu-se que o quitosano é um material adequado à produção de DM inovadores e que pode ser manipulável em estruturas para diferentes aplicações

Integrated disease management : an experimental approach in health management

The health systems are faced with new paradigms, on one hand in the healthcare services delivered to the populations, and on the other hand, in the need to control costs in the health sector, forcing organizations to adapt and provide the most appropriate response to the individuals growing needs. The magnitude of this problem, in terms of public health, requires the adoption of a directed, targeted, planned and integrated action, based on clear and well defined strategies in order to obtain health gains, improving the quality of care and streamlining the costs. In Portugal, the application of those principles forming the basis of the disease management models, led to the Integrated Disease Management model which, apart from the clinical management of the disease, also incorporates the healthcare delivery structure reorganization, a specific financing model based on an information system that allows the process monitoring and evaluation. The development of Integrated Disease Management models is a central strategy and a tool for improving healthcare delivery, more effectively and efficiently, and can even be an important and permanent vehicle of information for health decision support. Therefore, it is important to promote a concerted action towards achieving a precise intervention, mobilizing the resources, improving the health status, quality of life and the overall patients’ wellbeing. This action means increasing collaboration and coordination of the different levels of care, offering integrated healthcare services with high quality levels regarding prevention, diagnosis, treatment, rehabilitation and monitoring